Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 19 min ago
Peer-reviewedCC BY 4.0The Journal of Dermatology

Economic Burden and Treatment Patterns Among Patients Diagnosed With Vitiligo in Japan: An Observational Retrospective Cohort Study

  • Naoki Oiso1
  • Kent A. Hanson2
  • Ahmed M. Soliman2
  • Chao Li2
  • Manabu Taura3
  • Daniel Mercer4
  • Andrew Rava4
  • Danielle Bynoe4
  • Haiyan Sun4
  • Tamio Suzuki5,6
6 affiliations
  1. 1Department of Dermatology Kindai University Nara Hospital Ikoma Japan
  2. 2AbbVie Inc. North Chicago Illinois USA
  3. 3AbbVie GK Tokyo Japan
  4. 4Genesis Research Group Hoboken New Jersey USA
  5. 5Department of Dermatology Yamagata University Yamagata Japan
  6. 6Omoriekimae Hifuka Clinic Tokyo Japan
Read full textPDFDOICite

Abstract

Vitiligo, a common and chronic depigmentation disorder, significantly impacts patients' quality of life and exerts a substantial economic burden. The deleterious impact of vitiligo can be exacerbated by comorbid conditions, including psychiatric and autoimmune conditions. Treatment may vary across geographic regions, and there is sparse evidence of treatment patterns for vitiligo in Japan. Evaluations of healthcare costs are also needed to help underline unmet needs, including data on the influence of comorbid conditions on costs. Here we report results of a retrospective cohort analysis using claims data from the Japan Medical Data Center database to evaluate the economic burden and treatment patterns among patients with vitiligo in Japan. Primary study outcomes were costs and healthcare resource utilization (HCRU) 12 months post‐index (diagnosis date) for patients with vitiligo versus matched controls, based on inpatient, outpatient, and pharmacy claims. In total, 28 800 patients were included (4800 in the vitiligo cohort; 24 000 matched controls). Patients with vitiligo had significantly greater all‐cause healthcare costs (¥84 766 vs. ¥55 011, p < 0.0001) and HCRU than matched controls, primarily driven by outpatient, dermatology‐, and vitiligo‐related procedure costs. In patients with vitiligo, comorbid psychiatric and autoimmune conditions significantly increased all‐cause healthcare costs versus no comorbid condition (¥193 468 vs. ¥78 313 and ¥185 179 vs. ¥77 184, respectively; both p < 0.0001). Most patients (67.5%) did not receive treatment for vitiligo in the 12 months following diagnosis. Of those who did, 76.0% received only phototherapy. Only 2.2% received second‐line treatment. Overall, Japanese patients with vitiligo face substantially higher healthcare costs and resource utilization than those without vitiligo, with burden further increased by psychiatric and autoimmune comorbidities; notably, most remained untreated in the year after diagnosis, and treated patients primarily received phototherapy.

Related

  1. Economic burden of immune-mediated and psychiatric comorbidities in patients with newly diagnosed vitiligo
    David Rosmarin, Ahmed M. Soliman, Kent A. Hanson +4
    Journal of Managed Care & Specialty PharmacyPeer-reviewedLicence not statedFull textCell biologyPMC
  2. Initial treatment patterns and survival in biliary tract cancer: A retrospective cohort study in Kyoto, Japan
    Yukiko Tateyama, Sachiyo Shirakawa, Makoto Namba +10
    Cancer Treatment and Research CommunicationsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral biologyEpidemiology & public healthHAL
  3. Clinical characteristics and camouflaging behaviors in children and adolescents with late-diagnosed autism spectrum disorder: a retrospective descriptive study.
    Nazlı Burcu Özbaran, Zeynep İrem Şener, Seda Sarı +1
    Frontiers in child and adolescent psychiatryPeer-reviewedCC BYFull textNeuroscienceEurope PMC
  4. Characteristics and hospitalization burden of rare disease inpatients in Northern Henan, 2018–2025: a single-center retrospective observational study
    Danxia Ji, Kang Li, Nan Wang +4
    BMC Public HealthPeer-reviewedCC BY-NC-ND 4.0Genetics & genomicsCrossref
  5. AD-REAL: A Prospective, Multinational, Observational Cohort Study of Clinical Effectiveness and Treatment Discontinuation of Oral Systemics for Moderate-to-Severe Atopic Dermatitis
    Matthias Augustin, Andreas Pinter, Silvia Sabatino +8
    Dermatology and TherapyPeer-reviewedCC BY-NC 4.0Full textImmunologyHAL

Cite

BibTeXRIS
BibTeX
@article{oiso2026economic,
  title = {{Economic Burden and Treatment Patterns Among Patients Diagnosed With Vitiligo in Japan: An Observational Retrospective Cohort Study}},
  author = {Naoki Oiso and Kent A. Hanson and Ahmed M. Soliman and Chao Li and Manabu Taura and Daniel Mercer and Andrew Rava and Danielle Bynoe and Haiyan Sun and Tamio Suzuki},
  journal = {The Journal of Dermatology},
  year = {2026},
  month = aug,
  doi = {10.1111/1346-8138.70458},
  url = {https://doi.org/10.1111/1346-8138.70458},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Economic Burden and Treatment Patterns Among Patients Diagnosed With Vitiligo in Japan: An Observational Retrospective Cohort Study
AU  - Naoki Oiso
AU  - Kent A. Hanson
AU  - Ahmed M. Soliman
AU  - Chao Li
AU  - Manabu Taura
AU  - Daniel Mercer
AU  - Andrew Rava
AU  - Danielle Bynoe
AU  - Haiyan Sun
AU  - Tamio Suzuki
PY  - 2026
DA  - 2026/08/27
JO  - The Journal of Dermatology
DO  - 10.1111/1346-8138.70458
UR  - https://doi.org/10.1111/1346-8138.70458
AB  - Vitiligo, a common and chronic depigmentation disorder, significantly impacts patients' quality of life and exerts a substantial economic burden. The deleterious impact of vitiligo can be exacerbated by comorbid conditions, including psychiatric and autoimmune conditions. Treatment may vary across geographic regions, and there is sparse evidence of treatment patterns for vitiligo in Japan. Evaluations of healthcare costs are also needed to help underline unmet needs, including data on the influence of comorbid conditions on costs. Here we report results of a retrospective cohort analysis using claims data from the Japan Medical Data Center database to evaluate the economic burden and treatment patterns among patients with vitiligo in Japan. Primary study outcomes were costs and healthcare resource utilization (HCRU) 12 months post‐index (diagnosis date) for patients with vitiligo versus matched controls, based on inpatient, outpatient, and pharmacy claims. In total, 28 800 patients were included (4800 in the vitiligo cohort; 24 000 matched controls). Patients with vitiligo had significantly greater all‐cause healthcare costs (¥84 766 vs. ¥55 011, p < 0.0001) and HCRU than matched controls, primarily driven by outpatient, dermatology‐, and vitiligo‐related procedure costs. In patients with vitiligo, comorbid psychiatric and autoimmune conditions significantly increased all‐cause healthcare costs versus no comorbid condition (¥193 468 vs. ¥78 313 and ¥185 179 vs. ¥77 184, respectively; both p < 0.0001). Most patients (67.5%) did not receive treatment for vitiligo in the 12 months following diagnosis. Of those who did, 76.0% received only phototherapy. Only 2.2% received second‐line treatment. Overall, Japanese patients with vitiligo face substantially higher healthcare costs and resource utilization than those without vitiligo, with burden further increased by psychiatric and autoimmune comorbidities; notably, most remained untreated in the year after diagnosis, and treated patients primarily received phototherapy.
SN  - 0385-2407
SN  - 1346-8138
ER  -